Clinical significance of anti-insulin-antibodies.
Treatment of diabetic patients with common available insulin preparations in most cases results in formation of immuno-globulins called anti-insulin-antibodies. During the last 10-15 years it has been established, that these immuno-globulins, especially IgE, may be responsible for allergical manifestations. Moreover it has been established, that immuno-globulins, especially IgM, may be responsible for insulin resistance in many cases. It is concluded, that anti-insulin-antibodies also are important for the insulin requirement in non-resistant diabetics. The investigations could not reveal any significance of anti-insulin-antibodies for the degree of regulation. The remission period has been defined, 45 per cent of patients examined fulfilled the criteria for remission. The investigations support the assumption, that anti-insulin-antibodies may shorten the remission period, probably due to neutralizing effect upon the endogenous insulin supply. Finally our findings are in accordance with the view, that insulin-anti-insulin-antibody complexes might deteriorate late diabetic vascular complications.
D000293:Adolescent; D000328:Adult; D001666:Binding Sites, Antibody; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007073:Immunoglobulin E / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007328:Insulin / Q000276:immunology / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000096:biosynthesis; D007333:Insulin Resistance
D007075:Immunoglobulin M; D007328:Insulin; D007330:Insulin Antibodies; D007073:Immunoglobulin E